Uncertainty in Pharmacology Epistemology, Methods, and Decisions /
| Corporate Author: | |
|---|---|
| Other Authors: | , |
| Summary: | XIII, 470 p. 48 illus. text |
| Language: | English |
| Published: |
Cham :
Springer International Publishing : Imprint: Springer,
2020.
|
| Edition: | 1st ed. 2020. |
| Series: | Boston Studies in the Philosophy and History of Science,
338 |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/978-3-030-29179-2 |
| Format: | Electronic Book |
Table of Contents:
- Part I. Epistemology
- 1. Defining Aspects of Mechanisms: Evidence-Based Mechanism (Evidence for a Mechanism), Mechanism-Based Evidence (Evidence from a Mechanism), and Mechanistic Reasoning
- 2. Causal Insights from Failure: Post-Marketing Risk Assessment of Drugs as aWay to Uncover Causal Mechanisms
- 3. Extrapolating from Model Organisms in Pharmacology
- 4. "Mechanistic Versus Statistical Extrapolation in Preclinical Research in Psychiatry: Challenging the Received View"
- 5. Analogy-Based Inference Patterns in Pharmacological Research
- 6. "In Silico Clinical Trials: a Possible Response to Complexity in Pharmacology"
- 7. "Uncertainty in Drug Discovery: Strategies, Heuristics and Technologies"
- 8. “Caught in the Amber”: a Sketch of Chemical Underdetermination
- Part II. Methods
- 9. A Millian Look at the Logic of Clinical Trials
- 10. "Learning by Difference: Placebo Effects and Specific Efficacy in Pharmacological RCTs"
- 11. "An Evidence-Hierarchical Decision Aid for Rankingin Evidence-Based Medicine"
- 12. "Assessing Drug Safety Assessment: Metformin Associated Lactic Acidosis"
- 13. Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimer’s Measurement
- 14. "Modelling Individual Response to Treatment and its Uncertainty: a Review of Statistical Methods and Challenges for Future Research"
- Part III. Decisions
- 15. Values in Pharmacology
- 16. "Humbug, the Council of Pharmacy and Chemistry, and the Origin of “the Blind Test” of Therapeutic Efficacy"
- 17. On the Normative Foundations of Pharmaceutical Regulation
- 18. After Disclosure
- 19. Sex, Drugs, and how to Deal with Criticism—The Case of Flibanserin.